You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,255,143

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,255,143

Title:	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Abstract:	The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose.
Inventor(s):	Bengea; Cornelia (Auburn, MA), Rives; Lisa M. (Natick, MA), Hossler; Patrick (Westborough, MA)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	14/619,799
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,255,143
Patent Claims:	1. A composition comprising adalimumab, wherein more than 25% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F). 2. The composition of claim 1, wherein 26-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F). 3. The composition of claim 1, wherein 35-44% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F). 4. The composition of claim 1, wherein 30-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F). 5. The composition of claim 1, wherein less than 70% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc). 6. The composition of claim 5, wherein 49-69% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc). 7. The composition of claim 5, wherein 55-65% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc). 8. The composition of claim 1, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media which has been supplemented with a manganese supplement and a galactose supplement. 9. The composition of claim 1, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media comprising 0.2-100 .mu.M of a manganese supplement and 1-100 mM of a galactose supplement. 10. The composition of claim 9, wherein the cell culture media comprises a hydrolysate based media or a chemically defined media. 11. The composition of claim 9, wherein the mammalian cell is a CHO cell. 12. The pharmaceutical composition of claim 11 and a pharmaceutically acceptable carrier comprising a polyalcohol. 13. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable carrier further comprises polysorbate 80. 14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is suitable for subcutaneous administration and is formulated in a pre-filled syringe. 15. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier. 16. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises mannitol. 17. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises sodium chloride. 18. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises polysorbate 80. 19. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises sodium phosphate. 20. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is suitable for parenteral administration. 21. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is suitable for subcutaneous administration and is formulated in a pre-filled syringe.

Details for Patent 9,255,143

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2031-04-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2031-04-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2031-04-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014	⤷ Try a Trial	2031-04-27
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015	⤷ Try a Trial	2031-04-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.